CA2294590A1 - Antagonistes des adrenorecepteurs alpha 1a - Google Patents

Antagonistes des adrenorecepteurs alpha 1a Download PDF

Info

Publication number
CA2294590A1
CA2294590A1 CA002294590A CA2294590A CA2294590A1 CA 2294590 A1 CA2294590 A1 CA 2294590A1 CA 002294590 A CA002294590 A CA 002294590A CA 2294590 A CA2294590 A CA 2294590A CA 2294590 A1 CA2294590 A1 CA 2294590A1
Authority
CA
Canada
Prior art keywords
difluorophenyl
ylamino
oxo
carboxylic acid
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002294590A
Other languages
English (en)
Inventor
Michael A. Patane
Mark G. Bock
Randall C. Newton
Bharat Lagu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Synaptic Pharmaceutical Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800217.3A external-priority patent/GB9800217D0/en
Application filed by Individual filed Critical Individual
Publication of CA2294590A1 publication Critical patent/CA2294590A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention se rapporte à certains nouveaux composés et dérivés de ces composés, à leur synthèse et à leur utilisation en tant qu'antagonistes des adrénorécepteurs alpha 1a. L'une des applications de ces composés se fait dans le traitement de l'hyperplasie prostatique bénigne. Ces composés sont sélectifs du point de vue de leur capacité à provoquer la détente de tissus des muscles lisses enrichis par un récepteur du sous-type alpha 1a et ce, sans entraîner d'hypotension. L'un de ces tissus entoure la tunique urétrale. Par conséquent, les composés selon l'invention peuvent être utilisés pour induire un soulagement prononcé chez les hommes souffrant de l'hyperplasie prostatique bégnigne du fait qu'ils permettent un écoulement de l'urine plus facile. Les composés selon la présente invention peuvent également être utilisés en combinaison avec un composé inhibiteur de la réductase 5-alpha humaine et ce, de manière à induire un soulagement prononcé et chronique concernant les effets de l'hyperplasie prostatique bénigne.
CA002294590A 1997-06-18 1998-06-17 Antagonistes des adrenorecepteurs alpha 1a Abandoned CA2294590A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5095997P 1997-06-18 1997-06-18
US60/050,959 1997-06-18
GBGB9800217.3A GB9800217D0 (en) 1998-01-07 1998-01-07 Alpha 1a adrenergic receptor antagonists
GB9800217.3 1998-01-07
PCT/US1998/012567 WO1998057638A1 (fr) 1997-06-18 1998-06-17 ANTAGONISTES DES ADRENORECEPTEURS ALPHA 1a

Publications (1)

Publication Number Publication Date
CA2294590A1 true CA2294590A1 (fr) 1998-12-23

Family

ID=26312896

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002294590A Abandoned CA2294590A1 (fr) 1997-06-18 1998-06-17 Antagonistes des adrenorecepteurs alpha 1a

Country Status (5)

Country Link
EP (1) EP1023068A4 (fr)
JP (1) JP2002511085A (fr)
AU (1) AU7972698A (fr)
CA (1) CA2294590A1 (fr)
WO (1) WO1998057638A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207444B1 (en) 1997-08-05 2001-03-27 Merck & Co., Inc. Enzymatic process of making alpha 1a adrenergic receptor antagonists using protease
WO2000006565A1 (fr) 1998-07-30 2000-02-10 Merck & Co., Inc. ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005092341A1 (fr) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Therapie combinee destinee a reduire les symptomes des voies urinaires
WO2009131196A1 (fr) * 2008-04-24 2009-10-29 武田薬品工業株式会社 Dérivé de pyrrolidine substituée et ses utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists

Also Published As

Publication number Publication date
WO1998057638A1 (fr) 1998-12-23
JP2002511085A (ja) 2002-04-09
AU7972698A (en) 1999-01-04
EP1023068A1 (fr) 2000-08-02
EP1023068A4 (fr) 2001-05-16

Similar Documents

Publication Publication Date Title
US5661163A (en) Alpha-1a adrenergic receptor antagonists
CA2293408A1 (fr) Antagonistes du recepteur adrenergique alpha 1a
CA2294590A1 (fr) Antagonistes des adrenorecepteurs alpha 1a
US6358959B1 (en) Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
CA2294346A1 (fr) Antagonistes du recepteur adrenergique alpha 1a
WO1999025345A1 (fr) Antagonistes des recepteurs adrenergiques alpha-1a
CA2294344A1 (fr) Antagonistes du recepteur adrenergique alpha 1a
CA2294349A1 (fr) Antagonistes du recepteur adrenergique alpha 1a
US6255315B1 (en) Alpha 1a adrenergic receptor antagonists
CA2294591A1 (fr) Antagonistes des adrenorecepteurs alpha 1a
US6376503B1 (en) Alpha 1a adrenergic receptor antagonists
US5807856A (en) Alpha 1a adrenergic receptor antagonist
US6143750A (en) Alpha 1a adrenergic receptor antagonists
US6080760A (en) Alpha 1A adrenergic receptor antagonists
US6057350A (en) Alpha 1a adrenergic receptor antagonists
US6319932B1 (en) Oxazolidinones useful as alpha 1A adrenoceptor antagonists
EP0853479A1 (fr) ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1b
US6214832B1 (en) Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US5922722A (en) Alpha 1a adrenergic receptor antagonists
US5747490A (en) Alpha 1b adrenergic receptor antagonists
AU710337B2 (en) Alpha 1a adrenergic receptor antagonists
US6235759B1 (en) Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists
WO2000027827A1 (fr) Oxazolidinones utiles en tant qu'antagonistes du recepteur alpha 1a adrenergique
WO1997018209A1 (fr) ANTAGONISTES DE RECEPTEURS ADRENERGIQUES ALPHA 1a
WO2000027817A1 (fr) Oxazolidinones utiles en tant qu'antagonistes du recepteur alpha 1a adrenergique

Legal Events

Date Code Title Description
FZDE Dead